159 related articles for article (PubMed ID: 9703296)
1. Drug-induced parkinsonism as a risk factor for Parkinson's disease: a historical cohort study in Olmsted County, Minnesota.
Chabolla DR; Maraganore DM; Ahlskog JE; O'Brien PC; Rocca WA
Mayo Clin Proc; 1998 Aug; 73(8):724-7. PubMed ID: 9703296
[TBL] [Abstract][Full Text] [Related]
2. Motor and non-motor features of Parkinson's disease that predict persistent drug-induced Parkinsonism.
Morley JF; Pawlowski SM; Kesari A; Maina I; Pantelyat A; Duda JE
Parkinsonism Relat Disord; 2014 Jul; 20(7):738-42. PubMed ID: 24742370
[TBL] [Abstract][Full Text] [Related]
3. Number of children and risk of Parkinson's disease.
Frigerio R; Breteler MM; de Lau LM; Sanft KR; Bower JH; Ahlskog JE; Grossardt BR; ; Maraganore DM; Rocca WA
Mov Disord; 2007 Apr; 22(5):632-9. PubMed ID: 17265462
[TBL] [Abstract][Full Text] [Related]
4. Risk of cancer after the diagnosis of Parkinson's disease: a historical cohort study.
Elbaz A; Peterson BJ; Bower JH; Yang P; Maraganore DM; McDonnell SK; Ahlskog JE; Rocca WA
Mov Disord; 2005 Jun; 20(6):719-25. PubMed ID: 15704188
[TBL] [Abstract][Full Text] [Related]
5. Prospective study of coffee consumption and risk of Parkinson's disease.
Sääksjärvi K; Knekt P; Rissanen H; Laaksonen MA; Reunanen A; Männistö S
Eur J Clin Nutr; 2008 Jul; 62(7):908-15. PubMed ID: 17522612
[TBL] [Abstract][Full Text] [Related]
6. Levodopa-dyskinesia incidence by age of Parkinson's disease onset.
Kumar N; Van Gerpen JA; Bower JH; Ahlskog JE
Mov Disord; 2005 Mar; 20(3):342-4. PubMed ID: 15580606
[TBL] [Abstract][Full Text] [Related]
7. Dynamics of parkinsonism-Parkinson's disease in residents of adjacent kibbutzim in Israel's Negev.
Goldsmith JR; Herishanu YO; Podgaietski M; Kordysh E
Environ Res; 1997; 73(1-2):156-61. PubMed ID: 9311541
[TBL] [Abstract][Full Text] [Related]
8. Risk of Parkinson's disease following zolpidem use: a retrospective, population-based cohort study.
Huang HC; Tsai CH; Muo CH; Lin KH; Lu MK; Sung FC; Kao CH
J Clin Psychiatry; 2015 Jan; 76(1):e104-10. PubMed ID: 25650675
[TBL] [Abstract][Full Text] [Related]
9. Complex segregation analysis of Parkinson's disease: The Mayo Clinic Family Study.
McDonnell SK; Schaid DJ; Elbaz A; Strain KJ; Bower JH; Ahlskog JE; Maraganore DM; Rocca WA
Ann Neurol; 2006 May; 59(5):788-95. PubMed ID: 16634030
[TBL] [Abstract][Full Text] [Related]
10. Familial aggregation of Parkinson's disease: The Mayo Clinic family study.
Rocca WA; McDonnell SK; Strain KJ; Bower JH; Ahlskog JE; Elbaz A; Schaid DJ; Maraganore DM
Ann Neurol; 2004 Oct; 56(4):495-502. PubMed ID: 15455403
[TBL] [Abstract][Full Text] [Related]
11. Epidemiology of parkinsonism: incidence, classification, and mortality.
Rajput AH; Offord KP; Beard CM; Kurland LT
Ann Neurol; 1984 Sep; 16(3):278-82. PubMed ID: 6333204
[TBL] [Abstract][Full Text] [Related]
12. The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980-2002.
Kitzmann AS; Pulido JS; Diehl NN; Hodge DO; Burke JP
Ophthalmology; 2008 Jan; 115(1):169-73. PubMed ID: 18166410
[TBL] [Abstract][Full Text] [Related]
13. Fracture risk after the diagnosis of Parkinson's disease: Influence of concomitant dementia.
Melton LJ; Leibson CL; Achenbach SJ; Bower JH; Maraganore DM; Oberg AL; Rocca WA
Mov Disord; 2006 Sep; 21(9):1361-7. PubMed ID: 16703587
[TBL] [Abstract][Full Text] [Related]
14. Chemical exposures and Parkinson's disease: a population-based case-control study.
Frigerio R; Sanft KR; Grossardt BR; Peterson BJ; Elbaz A; Bower JH; Ahlskog JE; de Andrade M; Maraganore DM; Rocca WA
Mov Disord; 2006 Oct; 21(10):1688-92. PubMed ID: 16773614
[TBL] [Abstract][Full Text] [Related]
15. Young onset Parkinson's disease.
Quinn N; Critchley P; Marsden CD
Mov Disord; 1987; 2(2):73-91. PubMed ID: 3504266
[TBL] [Abstract][Full Text] [Related]
16. How does parkinsonism start? Prodromal parkinsonism motor changes in idiopathic REM sleep behaviour disorder.
Postuma RB; Lang AE; Gagnon JF; Pelletier A; Montplaisir JY
Brain; 2012 Jun; 135(Pt 6):1860-70. PubMed ID: 22561644
[TBL] [Abstract][Full Text] [Related]
17. Incidence and time trends of drug-induced parkinsonism: A 30-year population-based study.
Savica R; Grossardt BR; Bower JH; Ahlskog JE; Mielke MM; Rocca WA
Mov Disord; 2017 Feb; 32(2):227-234. PubMed ID: 27779780
[TBL] [Abstract][Full Text] [Related]
18. Environmental risk factors for Parkinson's disease and parkinsonism: the Geoparkinson study.
Dick FD; De Palma G; Ahmadi A; Scott NW; Prescott GJ; Bennett J; Semple S; Dick S; Counsell C; Mozzoni P; Haites N; Wettinger SB; Mutti A; Otelea M; Seaton A; Söderkvist P; Felice A;
Occup Environ Med; 2007 Oct; 64(10):666-72. PubMed ID: 17332139
[TBL] [Abstract][Full Text] [Related]
19. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990.
Van Gerpen JA; Kumar N; Bower JH; Weigand S; Ahlskog JE
Arch Neurol; 2006 Feb; 63(2):205-9. PubMed ID: 16476808
[TBL] [Abstract][Full Text] [Related]
20. Is 6 months of neuroleptic withdrawal sufficient to distinguish drug-induced parkinsonism from Parkinson's disease?
Lim TT; Ahmed A; Itin I; Gostkowski M; Rudolph J; Cooper S; Fernandez HH
Int J Neurosci; 2013 Mar; 123(3):170-4. PubMed ID: 23078283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
